Centessa Pharmaceuticals plc financial data

Symbol
CNTA on Nasdaq
Industry
Pharmaceutical Preparations
Location
3 Rd Floor, 1 Ashley Road, Altrincham, Cheshire, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Centessa Pharmaceuticals Ltd (to 5/24/2021)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1K % -14.9%
Debt-to-equity 46.8 % +35.5%
Return On Equity -63.1 % -16.8%
Return On Assets -43 % -7.05%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 113M shares +16.3%
Common Stock, Shares, Outstanding 113M shares +18.8%
Entity Public Float 311M USD +28.7%
Common Stock, Value, Issued 309K USD +16.2%
Weighted Average Number of Shares Outstanding, Basic 109M shares +15.1%
Weighted Average Number of Shares Outstanding, Diluted 109M shares +15.1%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 48.9M USD -11.7%
Operating Income (Loss) -155M USD +16.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -158M USD +19.8%
Income Tax Expense (Benefit) -496K USD +97.9%
Net Income (Loss) Attributable to Parent -157M USD +8.86%
Earnings Per Share, Basic -1.56 USD/shares +13.8%
Earnings Per Share, Diluted -1.56 USD/shares +13.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 127M USD -12.3%
Other Assets, Current 1.95M USD -49.5%
Assets, Current 356M USD +1.45%
Deferred Income Tax Assets, Net 28.6M USD +6.86%
Property, Plant and Equipment, Net 903K USD -21.1%
Operating Lease, Right-of-Use Asset 11.5M USD -7.06%
Other Assets, Noncurrent 2.38M USD +5.03%
Assets 399M USD +1.51%
Accounts Payable, Current 5.32M USD -52%
Employee-related Liabilities, Current 4.08M USD -9.53%
Accrued Liabilities, Current 21.4M USD -5.91%
Liabilities, Current 26.8M USD -21%
Operating Lease, Liability, Noncurrent 8.6M USD -6.03%
Other Liabilities, Noncurrent 29K USD
Liabilities 112M USD -3.81%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.6M USD +68.6%
Retained Earnings (Accumulated Deficit) -835M USD -23.2%
Stockholders' Equity Attributable to Parent 287M USD +3.75%
Liabilities and Equity 399M USD +1.51%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.3M USD +22.1%
Net Cash Provided by (Used in) Financing Activities 10.5M USD
Net Cash Provided by (Used in) Investing Activities 16.8M USD
Common Stock, Shares Authorized 184M shares +21%
Common Stock, Shares, Issued 113M shares +18.8%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.81M USD +92.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 127M USD -12.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.53M USD +7.89%
Deferred Tax Assets, Valuation Allowance 73.2M USD -22%
Deferred Tax Assets, Gross 106M USD +8.47%
Operating Lease, Liability 9.15M USD -4.79%
Depreciation 86K USD +132%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -157M USD +8.13%
Lessee, Operating Lease, Liability, to be Paid 14.8M USD -9.66%
Property, Plant and Equipment, Gross 1.54M USD +7.34%
Operating Lease, Liability, Current 552K USD +20%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.67M USD +2.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.63M USD +2%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Deferred Income Tax Expense (Benefit) 434K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.68M USD -16.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.7M USD +1.98%
Deferred Tax Assets, Operating Loss Carryforwards 77.4M USD +5.94%
Unrecognized Tax Benefits 2.61M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.73M USD +2%
Operating Lease, Payments 400K USD
Additional Paid in Capital 1.12B USD +17.5%
Depreciation, Depletion and Amortization 240K USD +170%
Deferred Tax Assets, Net of Valuation Allowance 32.4M USD +822%
Share-based Payment Arrangement, Expense 31.8M USD +13.2%
Interest Expense 10.1M USD +24.2%